In spite of a number of advantages of human adenovirus (HAd) vectors as a delivery system for a variety of gene therapy and vaccine applications, the vector immunity is one of the major disadvantages associated with these vectors. This is due to the presence of preexisting HAd-specific immunity in the majority of the human population and the development of a vector-specific immune response following the first inoculation. HAd-specific immunity significantly lowers the efficiency of HAd vector uptake following readministration of the same vector and thus drastically reduces the levels and duration of transgene expression. Another major concern associated with HAd vectors is an acute inflammatory response and hepatotoxicity caused by activation of innate immunity. Our hypothesis is that the primary receptors for HAd5, bovine adenovirus type 3 (BAd3) and porcine adenovirus type 3 (PAd3) are distinct, and therefore, the repertoire of cell types transduced by these adenoviral vectors will be different. This proposal addresses the core issue of eluding vector immunity by sequential administration of human and nonhuman adenoviral vectors. This will avoid toxicity and allow a reduction of the vector dose per inoculation without compromising the therapeutic effect.
Under Specific Aim 1, the efficacy of nonhuman adenoviral vectors for gene therapy will be evaluated. In particular, transduction efficiency, the level and persistence of the vector and expression of the vector gene/s will be determined.
Specific Aim 2 addresses the role of known adenoviral receptors and co-receptors in internalization of nonhuman adenoviral vectors. Subsequently, a series of in vivo experiments will be conducted to evaluate the usefulness of sequential administration of human and nonhuman adenoviral vectors in circumventing the vector-specific immune response and toxicity (Specific Aim 3). These in vivo experiments will be done in normal immunocompetent mice and major histocompatibility complex (MHC) class I-deficient mice to determine the role of cytotoxic T cells in limiting vector transduction, persistence and biodistribution. Additional experiments will be carried out in a mouse model of breast cancer to determine if differences in gene expression and toxicity occur following intravenous vs. intratumoral inoculation. The successful completion of this project should provide an effective strategy for circumvention of adenoviral vector immunity and toxicity for gene therapy applications.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA110176-04
Application #
7356063
Study Section
Special Emphasis Panel (ZRG1-GDD (01))
Program Officer
Daschner, Phillip J
Project Start
2005-04-01
Project End
2010-02-28
Budget Start
2008-03-01
Budget End
2010-02-28
Support Year
4
Fiscal Year
2008
Total Cost
$223,763
Indirect Cost
Name
Purdue University
Department
Type
Organized Research Units
DUNS #
072051394
City
West Lafayette
State
IN
Country
United States
Zip Code
47907
Hassan, Ahmed O; Vemula, Sai V; Sharma, Anurag et al. (2017) 155R is a novel structural protein of bovine adenovirus type 3, but it is not essential for virus replication. J Gen Virol 98:749-753
Ahi, Yadvinder S; Mittal, Suresh K (2016) Components of Adenovirus Genome Packaging. Front Microbiol 7:1503
Tandon, Manish; Vemula, Sai V; Sharma, Anurag et al. (2012) EphrinA1-EphA2 interaction-mediated apoptosis and FMS-like tyrosine kinase 3 receptor ligand-induced immunotherapy inhibit tumor growth in a breast cancer mouse model. J Gene Med 14:77-89
Tandon, Manish; Sharma, Anurag; Vemula, Sai V et al. (2012) Sequential administration of bovine and human adenovirus vectors to overcome vector immunity in an immunocompetent mouse model of breast cancer. Virus Res 163:202-11
Tandon, Manish; Vemula, Sai Vikram; Mittal, Suresh K (2011) Emerging strategies for EphA2 receptor targeting for cancer therapeutics. Expert Opin Ther Targets 15:31-51
Ahi, Yadvinder S; Bangari, Dinesh S; Mittal, Suresh K (2011) Adenoviral vector immunity: its implications and circumvention strategies. Curr Gene Ther 11:307-20
Sharma, Anurag; Bangari, Dinesh S; Vemula, Sai V et al. (2011) Persistence and the state of bovine and porcine adenoviral vector genomes in human and nonhuman cell lines. Virus Res 161:181-7
Sharma, Anurag; Bangari, Dinesh S; Tandon, Manish et al. (2010) Evaluation of innate immunity and vector toxicity following inoculation of bovine, porcine or human adenoviral vectors in a mouse model. Virus Res 153:134-42
Sharma, A; Tandon, M; Ahi, Y S et al. (2010) Evaluation of cross-reactive cell-mediated immune responses among human, bovine and porcine adenoviruses. Gene Ther 17:634-42
Li, Xiaoxin; Bangari, Dinesh S; Sharma, Anurag et al. (2009) Bovine adenovirus serotype 3 utilizes sialic acid as a cellular receptor for virus entry. Virology 392:162-8

Showing the most recent 10 out of 18 publications